Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Evenity Market Size And Revenue Forecast Through 2030
The expansion observed during the historic period was driven by several key factors, including an aging female demographic, a widespread occurrence of postmenopausal osteoporosis, the shortcomings associated with antiresorptive medications, elevated rates of fracture-linked morbidity, and the initial positive outcomes from biologic bone treatments.
The forecast period’s expansion is driven by heightened awareness of bone health, a surge in osteoporosis screenings, broader application of biologics, improved healthcare availability for older adults, and favorable reimbursement policies for fracture prevention. Key developments expected include the increased adoption of anabolic osteoporosis treatments, a stronger emphasis on minimizing fracture risks, a shift toward monthly injectable options, short-term osteoporosis regimens with high effectiveness, and the incorporation of biologic therapies into bone health management.
Download A Free Sample Report For Comprehensive Market Insights:
Evenity Market Development Factors: Which Trends Are Supporting Demand?
The growing occurrence of osteoporosis is anticipated to fuel the evenity market’s expansion moving forward. Osteoporosis is a health issue marked by reduced bone density and quality, causing bones to become fragile and more susceptible to fractures. This rising prevalence stems from an aging population experiencing natural bone density loss and inactive lifestyles that compromise skeletal strength. Administered as a monthly injection for up to 12 months, evenity treats osteoporosis by enhancing bone formation, curbing bone resorption, and fortifying bones to prevent fractures. For example, in February 2023, the Royal Osteoporosis Society, a UK-based charity, submitted written evidence indicating that fragility fractures cost the NHS $5.89 billion (£4.5 billion) each year, with hip fractures alone representing $2.62 billion (£2 billion) of this expense. Consequently, the increasing prevalence of osteoporosis is propelling the evenity market’s growth.
A rise in drug approvals is forecasted to boost the evenity market in upcoming years. Drug approvals refer to the formal assessment and authorization of pharmaceutical drugs by regulatory bodies for public use. This increase is mainly driven by biotechnological progress that accelerates drug discovery and supportive regulatory measures, like expedited approval programs, that simplify processes for medications in high demand. These approvals aid evenity growth by broadening the range of innovative therapies available, improving patient access, and building trust among healthcare professionals. For instance, in July 2024, the American Society of Gene and Cell Therapy (ASGCT), a US-based professional body, reported that in the second quarter of 2024, 76 gene therapy trials were launched, a 25% rise from the prior quarter. Hence, the growing number of drug approvals is driving the evenity market’s expansion.
Higher healthcare spending is expected to fuel the evenity market’s growth going forward. Healthcare expenditure encompasses all financial resources dedicated to medical services, preventive care, medications, and health-related pursuits aimed at improving or preserving population health. This spending is climbing due to increased medical needs from an aging populace and technological innovations that raise treatment expenses. Funds for evenity are directed toward covering drug costs, strengthening healthcare infrastructure, and improving osteoporosis treatment access, especially for older groups. For example, in May 2024, the Office for National Statistics, a UK government agency, noted that total healthcare expenditure grew by 5.6% in nominal terms from 2022 to 2023, a notable acceleration from the 0.9% rise seen in 2022. Therefore, rising healthcare expenditure is propelling the evenity market’s growth.
Evenity Market Segments: Where Are The Largest Growth Opportunities?
The evenity market covered in this report is segmented –
1) By Indication: Postmenopausal Osteoporosis, Osteoporosis In Men
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Hospitals And Clinics, Specialty Centers, Homecare Settings, Research And Academic Institutions
Evenity Market Major Participants And Competitive Dynamics
Major companies operating in the evenity market are Amgen Inc., UCB S.A
Access The Complete Evenity Market Report:
Evenity Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the evenity market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the evenity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model